Evidence map›Paper›PMID 35366160›Full record

ArticleJournal of endocrinological investigation2022

Erectile dysfunction as a marker of endocrine and glycemic disorders.

R Mazzilli, V Zamponi, S Olana, N Mikovic, D Cimadomo, G Defeudis, A Faggiano

Open access · hybridAbstract read
In one paragraph

Article in Journal of endocrinological investigation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
4.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Cardiometabolic Disorder and Erectile Dysfunction.Cell biochemistry and biophysics · 2024
    Review
  12. Article
  13. Diabetes technology and sexual health: which role?Journal of endocrinological investigation · 2024
    Review
  14. Article
  15. Role of Nutraceuticals in Treating Erectile DysfunctionCurrent pharmaceutical biotechnology · 2024
    Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

R MazzilliDepartment of Clinical and Molecular Medicine, University "Sapienza" of Rome, Sant'Andrea Hospital, Via di Grottarossa 1038, 00189, Rome, Italy. rossella.mazzilli@uniroma1.it.ORCID http://orcid.org/0000-0001-6707-3413
V ZamponiDepartment of Clinical and Molecular Medicine, University "Sapienza" of Rome, Sant'Andrea Hospital, Via di Grottarossa 1038, 00189, Rome, Italy.
S OlanaDepartment of Clinical and Molecular Medicine, University "Sapienza" of Rome, Sant'Andrea Hospital, Via di Grottarossa 1038, 00189, Rome, Italy.
N MikovicDepartment of Clinical and Molecular Medicine, University "Sapienza" of Rome, Sant'Andrea Hospital, Via di Grottarossa 1038, 00189, Rome, Italy.
D CimadomoGeneraLife IVF, Clinica Valle Giulia, via G. de Notaris 2b, Rome, Italy.
G DefeudisUnit of Endocrinology and Diabetes, Department of Medicine, University Campus Bio-Medico di Roma, Rome, Italy.
A FaggianoDepartment of Clinical and Molecular Medicine, University "Sapienza" of Rome, Sant'Andrea Hospital, Via di Grottarossa 1038, 00189, Rome, Italy.
Clinica Valle Giulia · ITCTO Andrea Alesini · ITUniversità Campus Bio-Medico · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe aim of this study was to evaluate in a population of patients with erectile dysfunction (ED): (a) the prevalence of a previously unknown endocrine/glycemic disorders; (b) the correlation between ED severity and endocrine/glycemic disorders.

methods1332 patients referred for ED from 2013 to 2020 were included. The ED diagnosis was made using the International-Erectile-Function-Index-5 questionnaire. ED severity was considered according to presence/absence of spontaneous erections, maintenance/achievement deficiency. All patients were subjected to search for sociodemographic and clinical characteristics: age, ethnicity, marital status, previous use of PDE5i, previous prostatectomy, diabetes mellitus (DM), prediabetes, endocrine dysfunctions.

resultsThe mean ± SD age was 54.3 ± 13.7 years. The 19.1% (255/1332) of patients were already in treatment for prediabetes/diabetes or endocrine dysfunctions. Among the remaining 1077, the prevalence of previously unknown endocrine and glycemic disorders was 30% (323/1077). Among them, 190/323 subjects (58.8%) were affected by hypogonadism, with high estradiol level observed in 8/190 (4.2%). The prevalence of new glycemic alterations was 17.3% (56/323) [specifically, 32/56 (57.1%) DM, and 24/56 (42.9%) prediabetes]. A thyroid dysfunction was observed in 40/323 subjects (12.3%) and hyperprolactinemia in 37/323 (11.5%). Patients with new diagnosis of DM showed more severe form of ED compared to the total group {difficulty in the achievement of erection: 46/56 [82.2%, vs 265/1332 (19.9%), p < 0.05]; absence of spontaneous erection 23/56 [41.1%, vs 321/1332 (24.1%), p < 0.05]}.

conclusionED is an early marker of endocrine/glycemic disorder, and a previously unknown dysfunction was found in more than a quarter of patients. A newly diagnosed DM is associated with ED severity, especially in elderly man and in presence of hypertension.

Indexed as

Diabetes MellitusErectile DysfunctionHypogonadismPrediabetic StateAdultAgedBiomarkersBlood GlucoseHumansMaleMiddle AgedBiomarkersBlood GlucoseDiabetes mellitus (DM)Erectile dysfunctionHypogonadismProlactinSexual functionThyroid dysfunction

Identifiers

PMID35366160
PMCPMC9270283
OpenAlexW4225771945

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.